×

HCG in News

News update | Healthcare Global Enterprises Ltd (HCG) partners with Trucan Diagnostics to Pioneer New Diagnostic Tests for Treatment Response Prediction and Monitoring in Cancer Patients

We are happy to inform that Healthcare Global Enterprises Ltd (HCG) has partnered with Trucan Diagnostics to Pioneer New Diagnostic Tests for Treatment Response Prediction and Monitoring in Cancer Patients. This partnership aims to validate a suite of novel diagnostic tests designed to improve detection of primary and recurrent/metastatic cancer precisely, predict therapy responses, and monitor treatment efficacy.

Under this partnership, HCG and Trucan will work together to conduct extensive validation studies on a new set of cancer diagnostic tests developed by Trucan. These tests employ advanced techniques, including next-generation sequencing and novel biomarker-driven diagnostics, to enable precise primary, recurrent/metastatic cancer detection, pre-treatment prediction of response to therapy and monitoring patients undergoing chemo or targeted therapy. The results of these studies will generate necessary data to assess and confirm the clinical utility of these tests, paving the way for their potential integration into routine clinical practice.

The news has been covered in print and online publications like ET Healthworld, BW Healthcare, Echo of India, Gujrat Business Watch, Dainik Vishwamitra, Prajavani, Express Healthcare, Daily Hunt Kannada, Prajavani Online, Pharmabiz, India Med Today, Medical Buyer, India Med today, Arthik Lippi, Janpath Samachar, Tapobhumi Gujrat, Sunvilla Samachar, Hans India, Samagya, Himalayan Mirror, Purbottar etc.

Attached and below are a few coverage links for reference.